Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06174259
Other study ID # 1998DRXVTF
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date June 1, 2023
Est. completion date June 1, 2025

Study information

Verified date January 2024
Source Menoufia University
Contact Yostena Mekhail, MD
Phone 800-545-5557
Email youstena.kamel@med.menofia.edu.eg
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Breast cancer is the most common cancer type among women in Egypt and world. Preclinical studies show fasting reduces growth factors and modulates nutrient sensing systems, protecting normal cells against chemotherapy. However, cancer cells are not protected due to Differential Stress Resistance (DSR), making them more vulnerable to chemotherapeutics. This study aims to evaluate intermittent fasting impact on neoadjuvant chemotherapy in breast cancer patients.


Recruitment information / eligibility

Status Recruiting
Enrollment 66
Est. completion date June 1, 2025
Est. primary completion date June 1, 2024
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - Female patients with stage II or III (cT1cN+ or =T2 any cN, cM0) breast cancer. - Planned to receive standard neoadjuvant chemotherapy. - Measurable disease (breast and/or lymph nodes). - WHO performance status 0-2. - Being overweight (BMI: 25-29.9 kg/m2) or obese (BMI: =30 kg/m2). - Adequate bone marrow function : white blood cells (WBCs) =3.0 x 109/l, neutrophils =1.5 x 109/l, platelets =100 x 109/l - Adequate liver function: bilirubin =1.5 x upper limit of normal (UNL) range, ALAT and/or ASAT =2.5 x UNL, Alkaline Phosphatase =5 x UNL - Adequate renal function: the calculated creatinine clearance should be =50 mL/min - Patients must be accessible for treatment and follow-up Exclusion Criteria: - Serious diseases such as recent myocardial infarction, clinical signs of cardiac failure or clinically significant arrhythmias - Diabetes Mellitus. - Pregnancy or lactating - Any metabolic disorders that may affect gluconeogenesis or adaptation to fasting periods. - Previous malignancy. - Using weight loss medication.

Study Design


Intervention

Other:
intermittent fasting
16/8 intermittent fasting (limiting foods and calorie-containing beverages to a set window of 8 hours per day)

Locations

Country Name City State
Egypt Menoufia university Shibin Al Kawm Menoufia

Sponsors (1)

Lead Sponsor Collaborator
Menoufia University

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary pathological response rate Assessment of pathological response using the Miller-Payne grading system; it is a grading system from 1-5 with 5 is the best response 6months
Secondary The percentage of patients with grade III/IV toxicity Common Terminology Criteria for Adverse Events (CTCAE) v5.0 6 months
Secondary Grade I/II side effects of chemotherapy Common Terminology Criteria for Adverse Events (CTCAE) v5.0 6 months
Secondary Clinical response Radiological before and after the NACT (neoadjuvant chemotherapy) using Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 6months
Secondary Body composition changes (fat, muscles, water) using Bioimpedance analysis (BIA) assessment before, 3months and at the end of NACT 6 months
Secondary Inflammatory response to chemotherapy. CRP level 6 months
Secondary Long term efficacy of treatment (DFS, OS) 5 years
See also
  Status Clinical Trial Phase
Completed NCT01048918 - Characterization of Circulating Tumor Cells (CTC-s) in Patients With Locally Advanced or Metastatic Stage IV Breast Cancer
Recruiting NCT05383196 - Onvansertib + Paclitaxel In TNBC Phase 1/Phase 2
Recruiting NCT05744375 - Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab Phase 2
Terminated NCT01837563 - Monitoring of Neoadjuvant Therapy in Locally-Advanced Breast Cancer N/A
Recruiting NCT03978663 - Three Fraction Radiation to Induce Immuno-Oncologic Response N/A
Active, not recruiting NCT04352777 - Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer Phase 2
Recruiting NCT06064812 - A Phase I Clinical Trial of FWD1802 in Patients With ER+/HER2- BC. Phase 1
Recruiting NCT05963997 - A Study of Samuraciclib and Elacestrant in Participants With Metastatic or Locally Advanced HR+/HER2-negative Breast Cancer Phase 1/Phase 2
Recruiting NCT06080620 - The Choice of Treatment Methods and Efficacy of LABC N/A
Completed NCT05002868 - Safety, Pharmacokinetics and Anti-tumor Activity of RP12146, in Patients With Solid Tumors Phase 1
Active, not recruiting NCT02595762 - A Study of Treatment Patterns and Outcomes in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced or Metastatic Breast Cancer
Active, not recruiting NCT02965950 - The p53 Breast Cancer Trial Phase 2
Completed NCT01785992 - A Study of the Safety and Effectiveness of Irosustat When Added to an AI in ER+ve Locally Advanced or Metastatic Breast Cancer. Phase 2
Completed NCT00764036 - Study of Artesunate in Metastatic Breast Cancer Phase 1
Active, not recruiting NCT03685331 - HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer Phase 1
Completed NCT05021900 - Efficacy and Safety of Tenalisib (RP6530), a PI3K δ/γ and SIK3 Inhibitor, in Patients With Locally Advanced or Metastatic Breast Cancer Phase 2
Withdrawn NCT04088032 - Neoadjuvant Study of Abemaciclib, Durvalumab, and an Aromatase Inhibitor Early Stage Breast Cancer Early Phase 1
Completed NCT00455273 - Dynamic Breast MRI in Assessing Locally Advanced Breast Cancer
Terminated NCT04042051 - Copanlisib in Combination With T-DM1 in Pretreated Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer Phase 1
Recruiting NCT05582499 - Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy Phase 1/Phase 2